HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4934-4940

  Bartoli, Manuela ^b,c   Al Shabrawey, Mohamed ^d   Labazi, Mohamed ^e   Ali Behzadian, M ^e   Istanboli, Mohamed ^e   El Remessy, Azza B ^f   Caldwell, Robert W ^e   Marcus, Dennis M ^b   Caldwell, Ruth B ^a,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IRCCS FONDAZIONE BIETTI   (Italy)

^d AUGUSTA UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERCELLULAR ADHESION MOLECULE 1; PIMONIDAZOLE; STAT3 PROTEIN; VASCULOTROPIN; HIF1A PROTEIN, MOUSE; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; NITROIMIDAZOLE DERIVATIVE; OXYGEN; STAT3 PROTEIN, MOUSE; SUPEROXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RETINOPATHY; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; CAPILLARY; DISEASE MODEL; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; PHOSPHORYLATION; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA;

ANIMALS; BLOTTING, WESTERN; CAPILLARIES; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDOLES; INFANT, NEWBORN; INTERCELLULAR ADHESION MOLECULE-1; LIPID PEROXIDATION; MICE; NITROIMIDAZOLES; OXYGEN; PHOSPHORYLATION; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; STAT3 TRANSCRIPTION FACTOR; SUPEROXIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349577808     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2158     Document Type: Article

References (42)

1. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003; 19(6):442-455.
2. Shama N, Inachulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006;19(3): 335-344.
3. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6(4):511-524.
4. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26(48):12439-12446.
5. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53-67.
6. Paraskevas KI, Tzovaras AA, Briana DD, Mikhaidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007;13(35):3622-3636.
7. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinical relevant? Eur Heart J. 2003;24(3): 225-248.
8. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(suppl 2):B72-B78.
9. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32(3):164-176.
10. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004;18(7):805-815.
11. Takayama T, Wada A, Tsutamoto T, et al. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J. 2004;68(11):1067-1075.
12. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167(2):599-607.
13. Miyara S, Kiryu J, Yamashiro Y, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol. 2004;164(5):1697-1706.
14. Al-Shabrawey M, Bartoli M, El-Remessy A, et al. Role of NAD(P)H oxidase and STAT3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49(7):3231-3238.
15. Bartoli M, Gu X, Tsai NT, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem. 2000;275(43):33189-33192.
16. Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003;17(11): 1562-1564.
17. Platt DH, Bartoli M, El-Remessy AB, et al. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic Biol Med. 2005;39(10):1353-1361.
18. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97(6):439-447.
19. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1): 101-111.
20. Gu X, El-Remessy AB, Brooks SE, Al-Shabrawey M, Tsai NT, Caldwell RB. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol. 2003;285(3):C546-C554.
21. Gu X, Samuel S, Al-Shabrawey M, et al. Effects of sustained hyperoxiaon revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2002;43(2):496-502.
22. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparins-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851-858.
23. Cusik M, Chew Ey, Chan CC, Kruth HS, Murphy RP, Ferris FL 3rd. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology. 2003;110(11):2126-2133.
24. Coccheri S. Approaches for prevention to cardiovascular complications and events in diabetes mellitus. Drugs. 2007;67(7):997-1026.
25. Guymer RH, Chiu AW, Lim L, Baird PN. HMG-CoA reductase inhibitors (statins) do they have a role in age-related macular degeneration? Surv Ophthalmol. 2005;50(2):194-206.
26. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137(4):675-682.
27. Lahera V, Goicoechea M, de Vinuesa SG, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007;14(2)243-248.
28. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K. Cytokine signaling: STATs in plasma membrane rafts. J Biol Chem. 2002;277(14): 12067-12074.
29. Zuo L, Ushio-Fukai M, Hilenski LL, Alexander RW. Microtubules regulate angiotensin II type 1 receptor and Rac-1 localization in caveolae/lipid rafts: role in redox signaling. Arterioscler Thromb Vasc Biol. 2004;24(7):1223-1228.
30. Ishida S, Yamashiro K, Usui T, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9(6):781-788.
31. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156(5):1733-1739.
32. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40(8):1808-1812.
33. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96(19):10836-10841.
34. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(6):2743-2749.
35. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retinal the role of hypoxia-inducible factors. Exp Eye Res. 2006;83(3): 473-483.
36. Hilfiker-Kleiner D, Limbourg A, Drexler H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med. 2005;15(4):152-157.
37. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008;28(2):185-200.
38. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factorinduced signaling and angiogenesis. Circ Res. 2002;91(12):1160-1167.
39. Ushio-Fukai M. VEGF signaling through NAD(P)H oxidase-derived ROS. Antioxid Redox Signal. 2007;9(6):731-739.
40. Urbich C, Dembach E, Ziher AM, Dimmeler S. Double-edge role of statins in angiogenesis signaling. Circ Res. 2002;90(6):737-744.
41. Vincent L, Soria C, Mirshahi F, et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol. 2002;22(4):623-629.
42. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739-745.